Overcoming Anti-PD-1 Resistance in Lung Cancer
Abstract
The goal of this proposal was to first define the cellular and molecular effector mechanisms that underlie our original observation, i.e. lung Th17 immunity drives anti-PD-1 resistance in lung cancer (Aim 1); and then determine whether the lung microbiota signature ultimately determines the severity of Th17 cell activity (Aim 2). All Aim 1 studies and part of Aim 2subtask 1 were completed in years 1 and 2 along with a publication (see Appendix). Year 3work saw the completion of Aim 2, subtasks 1 and 2, and the publication of a second manuscript(see Appendix). This concludes all proposed studies.
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 01, 2022
- Accession Number
- AD1192627
Entities
People
- Nejat K Egilmez
Organizations
- University of Louisville